<DOC>
	<DOCNO>NCT02976337</DOCNO>
	<brief_summary>Recent study focus role endogenous opioids central sensitization . Central sensitization know impaired alter chronic pain condition , fibromyalgia chronic tension headache . Animal study show reinstatement mechanical hypersensitivity follow naloxone administration resolution injury . This suggest latent sensitization . In present study , investigator hypothesize high-dose target-controlled naloxone infusion ( total dose : 3.25 mg/kg ) reinstate pain hyperalgesia 6-8 week unilateral primary open groin hernia repair procedure . The investigator aim show latent sensitization present human modulate endogenous opioids .</brief_summary>
	<brief_title>Effect High-dose Naloxone Following Third Molar Extraction</brief_title>
	<detailed_description>Naloxone combine mu-opioid-receptor ( MOR ) inverse agonist antagonist drug , dose-dependently demonstrate hypoalgesic hyperalgesic property . Systemically administrated naloxone ( 3.0-10.0 mg/kg ) naltrexone ( 0.3-3.0 mg/kg ) use rodent study role endogenous opioids central process pain . It hypothesize endogenous opioid modulation pain impair altered chronic pain condition . Administration naloxone naltrexone follow resolution inflammatory injury , demonstrate reinstatement hypersensitivity noxious stimulus , indicate demasking latent sensitization . It thus speculate endogenous opioid system may play important role transition acute chronic pain human . In early human study use electrical pain model , naloxone ( 21 microg/kg ) increase establish area secondary hyperalgesia ( measure central sensitization ) . In previous translational placebo-controlled , double-blind , randomize , cross-over study healthy human , investigator unable show naloxone-induced reinstatement secondary hyperalgesia resolution first-degree burn-injury ( BI ; H-2-2012-036 ) . The investigator hypothesize , negative result attributable low dose naloxone ( 21 microg/kg ) perhaps insufficient tissue injury generate latent sensitization . The investigator therefore sequel study administer high dose naloxone ( 2 mg/kg ) 7 day induction BI . The investigator demonstrate 4 12 subject reinstatement secondary hyperalgesia . The magnitude reinstatement pronounce high-sensitizers ( subject develop large secondary hyperalgesia area immediately BI ) The aims present clinical study patient first , replicate previous finding naloxone-induced ( 3.25 mg/kg ) unmask latent sensitization utilize impacted mandibular third molar extraction ( TME ) model pronounce tissue injury BI-model . The endpoint reinstatement pain hyperalgesia resolution-phase , 4 - 5 week TME-surgery . Second , study examines potential dose-response relationship three stable naloxone concentration acquire target control infusion ( TCI ) .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Hyperalgesia</mesh_term>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Pulpitis</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>INCLUSION CRITERIA : Healthy male Age , minimum 18 yr maximum 65 yr Signed inform consent Participants submit unilateral , primary , impacted , uncomplicated mandibular third molar extraction 4 week ( + 3 day ) prior examination Day 1 . Standardized surgical procedure . Urinsample without trace opioids ( morphine , methadon , buprenorphine , codeine , tramadol , ketobemidone , oxycodone , hydromorphone , dextromethorphan ) ASA III Body mass index ( BMI ) : 18 &lt; BMI &lt; 30 kg/m2 EXCLUSION CRITERIA : Participants , speak understand Danish Participants , cooperate investigation Participants , previous surgery mandibular region Participants pain rest &gt; 3 ( NRS [ 0 : pain ; 10 : worst perceivable pain ] ) Activityrelated pain surgical field &gt; 5 ( NRS ) Allergic reaction morphine opioids ( include naloxone ) , Abuse alcohol drug accord investigator 's evaluation Use psychotropic drug ( exception SSRI ) Neurologic psychiatric disease Chronic pain condition Regular use analgesic drug Skin lesion tattoo assessment area Nerve lesion assessment site ( e.g. , trauma , dental surgery ) Use prescription drug one week trial Use overthecounter ( OTC ) drug 48 hour trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Central sensitization</keyword>
	<keyword>Endogenous opioids</keyword>
	<keyword>Humans</keyword>
	<keyword>Latent sensitization</keyword>
	<keyword>Mandibular third molar extraction</keyword>
	<keyword>Naloxone</keyword>
	<keyword>Pain</keyword>
	<keyword>Pressure algometry</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Secondary hyperalgesia</keyword>
	<keyword>Target control infusion</keyword>
</DOC>